Fenwick Represents Cepheid in its $4 Billion Acquisition by Danaher

September 06, 2016

Fenwick & West represented Cepheid (NASDAQ: CPHD), a leading molecular diagnostics company, in its definitive agreement under which the Danaher Corporation (NYSE: DHR) will acquire all outstanding shares of Cepheid common stock for $53 per share in cash, or a total enterprise value of approximately $4 billion including indebtedness and net of acquired cash.

Cepheid's Board of Directors unanimously approved the transaction, which is expected to close in the fourth quarter of 2016, subject to Cepheid shareholder approval, clearances by the relevant regulatory authorities and other customary closing conditions. 

The Fenwick transaction team included corporate lawyers Doug Cogen, Michael Brown, Stephen Fisher, Morgan Sawchuk, Maureen Montgomery, Taylor Cashwell, Jeremy Kazzaz and Travis Robertson; intellectual property lawyers Ralph Pais, Joseph Schenck, Amy Hayden and Jung Yoo; antitrust lawyer Mark Ostrau; executive compensation and employee benefits lawyers Scott Spector and Patrick Grilli; and tax lawyers Will Skinner and Michael Knobler.​